EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Subscribe Community News More Cool Stuff Community News Pasadena Part of CVS COVID-19 Treatment Pilot Program Eligible patients can receive antibody therapy STAFF REPORT Published on Wednesday, December 2, 2020 | 5:51 pm faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Donald CommunityPCC- COMMUNITYVirtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyPasadena Public WorksPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Name (required) Mail (required) (not be published) Website Your email address will not be published. Required fields are marked * HerbeautyWant To Seriously Cut On Sugar? You Need To Know A Few TricksHerbeautyHerbeautyHerbeauty10 Most Influential Women In HistoryHerbeautyHerbeautyHerbeautyStop Eating Read Meat (Before It’s Too Late)HerbeautyHerbeautyHerbeautyA Mental Health Chatbot Which Helps People With DepressionHerbeautyHerbeautyHerbeautyIs It Bad To Give Your Boyfriend An Ultimatum?HerbeautyHerbeautyHerbeauty10 Questions To Start Conversation Way Better Than ‘How U Doing?’HerbeautyHerbeauty Make a comment STAFF REPORT Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Business News Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. 15 recommended0 commentsShareShareTweetSharePin it STAFF REPORT First Heatwave Expected Next Week CITY NEWS SERVICE/STAFF REPORT Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Top of the News CVS Health was selected today by the U.S. Department of Health and Human Services (HHS) to be part of Operation Warp Speed to pilot the administration of a limited supply of bamlanivimab, a monoclonal antibody therapy.The pilot is being rolled out in several cities, among them Los Angeles, which includes the Pasadena stores.“These newly available, important COVID-19 treatments can make a difference for patients at high risk for severe illness or complications, but they need to be administered intravenously by healthcare providers and with the appropriate clinical expertise and oversight,” said Dr. Sree Chaguturu, chief medical officer of CVS Caremark and senior vice president of CVS Health.“Our Coram model (the specialty pharmacy and infusion care business of CVS Health) allows us to meet patients where they are during the pandemic by delivering safe, clinically appropriate home-based care, and we stand ready to deploy our teams when and where the need is greatest as supply of these new monoclonal antibody treatments ramp up over the coming year,” said Chaguturu.COVID-19 patients at-risk of severe infection or complications resulting from the virus are eligible for the program.Under this pilot, Coram will administer the intravenous therapy in patients’ homes or long-term care facilities to help meet the growing demand for these new treatments.Coram and its more than 800 certified and highly trained nurses across the country are a prime example of how CVS Health offers diversified health services to transform health and meet people where they are – whether in normal times or during the ongoing pandemic.As COVID-19 rates surge in many parts of the country, Coram also has worked to help keep patients out of inpatient and hospital settings altogether, alleviating pressure on the healthcare system and preserving important hospital resources for the most critical patients.Since early in the pandemic, Coram has partnered with hospitals to safely transition eligible infusion patients home to help ensure hospital bed capacity to treat COVID-19 patients. Importantly, today’s announcement also expands the integral role of CVS Health on the front lines in the fight against COVID-19. This includes work underway with Health and Human Service and Operation Warp Speed to administer COVID-19 vaccines when available, as well as a national COVID-19 testing infrastructure, which has enabled the company to perform more than 8 million tests across more than 4,300 retail testing locations and onsite at workplaces and campuses around the country since the start of the pandemic.Coram will begin administering 1,000 doses of monoclonal antibody therapies for the treatment of COVID-19 in seven cities and their surrounding communities starting Thursday, Dec. 3, including Boston, Chicago, Cleveland, Los Angeles, Milwaukee, Minneapolis and Tampa, as new COVID-19 infections continue to rise rapidly in these regions.Following the pilot, and as drug supply increases, Coram will scale this solution to additional markets in areas of greatest need.To be eligible for bamlanivimab through Coram, and in accordance with the therapy’s Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration, patients must not be hospitalized, be within 10 days of symptom onset, at least 12 years of age or older, weighing at least 40 kilograms (or 88.2 pounds), and at high risk for progressing to severe disease and/or hospitalization.Patients can be referred to Coram for treatment from a hospital, urgent care or telemedicine appointment, long-term care facility or their primary care physician following a positive diagnosis. There is no out-of-pocket cost to the patient for this care.“Patients can rest assured they are receiving the best care possible through Coram in the safety and comfort of their own home or long-term care facility, and Coram is poised to continue to meet shifting health care demands as the importance and value of home-based care will undoubtedly outlive the pandemic,” added Prem Shah, Pharm.D., executive vice president of CVS specialty and product innovation.“This established and experienced clinical service further demonstrates CVS Health’s unique ability to touch all aspects of a person’s health to make their experience more accessible and affordable,” Shah said.More information on steps CVS Health has taken to address the COVID-19 pandemic is available at the company’s frequently updated COVID-19 resource center. Community News Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena
The new chief executive of Finnish local government and church pension fund Keva has resigned suddenly due to a crisis of confidence between him and the management board, the fund announced.Anna-Kaisa Ikonen, chairman of the Keva board, said: “Unfortunately, Jukka Männistö’s term is very short. “I would like to thank Männistö for his cooperation with the board and for his role in implementing changes in the management of Keva.”Keva, which has €41.5bn in investment assets, manages pensions for employees of local government, the state, the Evangelical Lutheran Church of Finland and benefits agency Kela. Keva said Männistö had handed in his letter of resignation to the board of directors on 30 September.“The reason behind the resignation is a crisis of confidence between the board and CEO Männistö,” the pension fund said.Ikonen was not immediately available for further comment.The pension fund said the resignation would be put into effect once Keva’s council approved it, adding that the next council meeting would take place on 8 October.But the process of appointing a new chief executive will begin immediately, it said, with the new leader likely to take up his or her post in the spring of 2016.“Despite the resignation of the CEO, Keva will continue to operate without disruption,” Keva said.Männistö’s appointment as chief executive was only announced last year in May. He was then taking over from Pekka Alanen, Keva’s deputy managing director, who had been acting as interim head following the resignation of Merja Ailus in November 2013.Ailus had become caught up in a scandal involving accusations over personal expenses, taxes and benefits.Following the scandal, Keva worked on reforming its management guidelines, saying it needed to develop a leadership culture by other means than just instructions and rules.
Kiss added: “What he brings to a team in terms of energy and enthusiasm is sensational. If he doesn’t get selected he is still the same person. He has an uncanny ability to score tries at international level. “Last week he shipped an injury in the game and he toughed his way through it. He trained through a bit of injury this week and got a knock in the game again but just keeps powering on. I can’t speak highly enough about him and the way he played.” Kiss could reflect with pride on a tour that has seen Ireland blood six new caps, including try scorer Tommy O’Donnell. “Without a doubt we found out a little about ourselves as players,” he said. “From a coaching perspective it was certainly encouraging on a lot of fronts. Sometimes the perception is you can come and get these tier two nations and run it away easily but they were both tough affairs. “I think it was the 54th minute it was 14-12. We had to find something, keep our composure and again fantastic leadership through Peter (O’Mahony). It pulled us through to a place where we could have the intent to attack as much as we can. And that ended up getting the tries for us. “(There were) six new caps and guys have learnt a lot about themselves. I think it has been a really good tour in that respect.” Press Association Ireland interim coach Les Kiss paid tribute to hat-trick hero Fergus McFadden after his crucial role in the tourists’ 40-14 win over Canada in Toronto. The Leinster winger scored three of his side’s six tries to end a difficult international season on a high. The Australian hands over to incoming coach Joe Schmidt on conclusion of a successful tour that saw the tourists struggle to a win in difficult conditions in Houston before romping home against Canada. McFadden played a part in Andrew Trimble’s opening try, before crossing for three of his own. He has been in and out of the international set-up all season, but Kiss believes he put his hand up for future selection with a big display. Kiss said: “Fergus is just one of those players you want to have around your team. He is such a great character.”